Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia.
作者信息
Venugopal Sangeetha, Maiti Abhishek, DiNardo Courtney D, Loghavi Sanam, Daver Naval G, Kadia Tapan M, Rausch Caitlin R, Alvarado Yesid, Ohanian Maro, Sasaki Koji, Short Nicholas J, Takahashi Koichi, Yilmaz Musa, Ravandi Farhad, Kantarjian Hagop M, Konopleva Marina Y
机构信息
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
出版信息
Am J Hematol. 2021 May 1;96(5):E154-E157. doi: 10.1002/ajh.26122. Epub 2021 Feb 19.
Abstract
摘要
相似文献
1
Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia.地西他滨和维奈克拉治疗异柠檬酸脱氢酶1/2突变的急性髓系白血病
Am J Hematol. 2021 May 1;96(5):E154-E157. doi: 10.1002/ajh.26122. Epub 2021 Feb 19.
2
Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.白血病遗传学与复发/难治性急性髓系白血病对维奈托克和去甲基化药物反应的关联
Am J Hematol. 2019 Oct;94(10):E253-E255. doi: 10.1002/ajh.25567. Epub 2019 Jul 10.
3
The feasibility of venetoclax and decitabine in therapy-related acute myeloid leukemia with concurrent advanced non-hematological malignancies.维奈托克和地西他滨用于治疗相关急性髓系白血病合并晚期非血液系统恶性肿瘤的可行性。
Leuk Res. 2019 Sep;84:106196. doi: 10.1016/j.leukres.2019.106196. Epub 2019 Jul 30.
4
Venetoclax plus decitabine induced complete remission with molecular response in acute myeloid leukemia relapsed after hematopoietic stem cell transplantation.维奈托克联合地西他滨可诱导造血干细胞移植后复发的急性髓系白血病完全缓解并伴有分子学反应。
Am J Hematol. 2019 Feb;94(2):E48-E50. doi: 10.1002/ajh.25352. Epub 2018 Nov 29.
5
Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable-risk acute myeloid leukemia.维奈托克联合低甲基化药物治疗低危急性髓系白血病的疗效
Am J Hematol. 2021 Mar 1;96(3):E59-E63. doi: 10.1002/ajh.26057. Epub 2020 Dec 8.
6
Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia-A multicenter cohort study.IDH1或IDH2突变的新诊断急性髓系白血病中，去甲基化药物与维奈托克联合治疗对比强化诱导化疗——一项多中心队列研究
Am J Hematol. 2024 Aug;99(8):1640-1643. doi: 10.1002/ajh.27366. Epub 2024 May 15.
7
Hypomethylating agents and venetoclax in acute myeloid leukemia.急性髓系白血病中的去甲基化药物与维奈克拉
Clin Adv Hematol Oncol. 2021 Feb;19(2):82-83.
8
Venetoclax with decitabine or azacitidine for AML.维奈托克联合地西他滨或阿扎胞苷治疗急性髓系白血病
Lancet Oncol. 2018 Dec;19(12):e672. doi: 10.1016/S1470-2045(18)30824-6. Epub 2018 Nov 1.
9
Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Venetoclax 联合治疗复发/难治性急性髓系白血病及相关髓系恶性肿瘤的临床经验。
Am J Hematol. 2018 Mar;93(3):401-407. doi: 10.1002/ajh.25000. Epub 2017 Dec 23.
10
Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.维奈克拉与去甲基化药物联合治疗复发/难治性急性髓系白血病的疗效
Haematologica. 2018 Sep;103(9):e404-e407. doi: 10.3324/haematol.2018.188094. Epub 2018 Mar 15.
引用本文的文献
1
Comprehensive view on chemotherapy-free management of acute myeloid leukemia by using venetoclax in combination with targeted and/or immune therapies.关于使用维奈托克联合靶向和/或免疫疗法对急性髓系白血病进行无化疗管理的综合观点。
Cell Death Discov. 2025 Aug 13;11(1):379. doi: 10.1038/s41420-025-02678-4.
2
Pyrimidine depletion enhances targeted and immune therapy combinations in acute myeloid leukemia.嘧啶耗竭增强急性髓系白血病的靶向和免疫治疗联合。
JCI Insight. 2024 Apr 22;9(8):e173646. doi: 10.1172/jci.insight.173646.
3
Myelomonocytic and monocytic acute myeloid leukemia demonstrate comparable poor outcomes with venetoclax-based treatment: a monocentric real-world study.基于维奈托克的治疗方案在治疗骨髓单核细胞白血病和单核细胞性急性髓细胞白血病方面显示出可比的不良预后：一项单中心真实世界研究。
Ann Hematol. 2024 Apr;103(4):1197-1209. doi: 10.1007/s00277-024-05646-7. Epub 2024 Feb 8.
4
The future paradigm of HMA + VEN or targeted inhibitor approaches: sequencing or triplet combinations in AML therapy.HMA+VEN 或靶向抑制剂方法的未来模式：AML 治疗中的测序或三联组合。
Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):192-197. doi: 10.1182/hematology.2023000429.
5
Test Then Erase? Current Status and Future Opportunities for Measurable Residual Disease Testing in Acute Myeloid Leukemia.检测后清除？急性髓系白血病中可测量残留疾病检测的现状和未来机遇。
Acta Haematol. 2024;147(2):133-146. doi: 10.1159/000535463. Epub 2023 Nov 30.
6
Current Advances and Future Strategies for BCL-2 Inhibitors: Potent Weapons against Cancers.BCL-2抑制剂的当前进展与未来策略：对抗癌症的有力武器
Cancers (Basel). 2023 Oct 12;15(20):4957. doi: 10.3390/cancers15204957.
7
Approach to the Older Patient with Acute Myeloid Leukemia.老年急性髓系白血病患者的处理方法。
Curr Oncol Rep. 2023 Nov;25(11):1203-1211. doi: 10.1007/s11912-023-01450-0. Epub 2023 Sep 9.
8
Update on Small Molecule Targeted Therapies for Acute Myeloid Leukemia.急性髓系白血病的小分子靶向治疗进展。
Curr Treat Options Oncol. 2023 Jul;24(7):770-801. doi: 10.1007/s11864-023-01090-3. Epub 2023 May 17.
9
Venetoclax and Azacitidine in Chinese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy.维奈托克与阿扎胞苷用于不适宜接受强化化疗的中国初治急性髓系白血病患者
Signal Transduct Target Ther. 2023 May 3;8(1):176. doi: 10.1038/s41392-023-01394-8.
10
The Growing Role of the BH3 Mimetic Drug Venetoclax in the Therapy of Acute Myeloid Leukemia.BH3模拟药物维奈克拉在急性髓系白血病治疗中日益重要的作用
Mediterr J Hematol Infect Dis. 2022 Nov 1;14(1):e2022080. doi: 10.4084/MJHID.2022.080. eCollection 2022.
本文引用的文献
1
Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia.突变型异柠檬酸脱氢酶 1 抑制剂伊维替尼联合阿扎胞苷治疗新诊断的急性髓系白血病。
J Clin Oncol. 2021 Jan 1;39(1):57-65. doi: 10.1200/JCO.20.01632. Epub 2020 Oct 29.
2
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.10天阿扎胞苷联合维奈克拉用于新诊断的不适合强化化疗以及复发或难治性急性髓系白血病的治疗：一项单中心2期试验
Lancet Haematol. 2020 Oct;7(10):e724-e736. doi: 10.1016/S2352-3026(20)30210-6. Epub 2020 Sep 5.
3
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.阿扎胞苷和维奈托克治疗未经治急性髓系白血病。
N Engl J Med. 2020 Aug 13;383(7):617-629. doi: 10.1056/NEJMoa2012971.
4
Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.一线 venetoclax 联合治疗老年 AML 患者后的反应和治疗失败的分子模式。
Blood. 2020 Mar 12;135(11):791-803. doi: 10.1182/blood.2019003988.
5
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.ivosidenib 可诱导新诊断的 IDH1 突变型急性髓系白血病患者深度持久缓解。
Blood. 2020 Feb 13;135(7):463-471. doi: 10.1182/blood.2019002140.
6
Enasidenib in mutant relapsed or refractory acute myeloid leukemia.恩杂鲁胺用于治疗突变型复发或难治性急性髓系白血病。 （注：原文中药物名可能有误，推测正确药物名应该是Enasidenib为恩杂鲁胺，而这里治疗白血病的应该是Enasentinib，中文名为恩西地平 ，以下按照正确药物名给出译文）
恩西地平用于治疗突变型复发或难治性急性髓系白血病。
Blood. 2017 Aug 10;130(6):722-731. doi: 10.1182/blood-2017-04-779405. Epub 2017 Jun 6.
Zotero 插件